Association details:
Evidence Level:
Sensitive: C4 – Case Studies

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab

Based on the elevated AFP and CT findings, the patient was considered to have relapsed metastatic HCC. He was started on standard therapy with sorafenib 200 mg orally twice a day for a week, then 400 mg orally twice a day... After five months of therapy with sorafenib, AFP increased from 2751 mcg/L to 8877 mcg/L...After informed consent to individual therapy, off-label treatment with the anti-PD-1 antibody pembrolizumab (2 mg/kg every three weeks) was initiated. After six cycles of therapy, a CT scan of the abdomen showed a major decrease in subxiphoid mass size from 8 x 6 cm to 4 x 1.6 cm (Figure ​(Figure2)2) and AFP dropped from 8877 mcg/L to 1.7 mcg/L. The patient tolerated therapy with pembrolizumab without adverse effects...